Wealth Enhancement Advisory Services’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$260K Sell
26,238
-96
-0.4% -$767 ﹤0.01% 3496
2026
Q2
$216K Sell
26,334
-1,294
-5% -$9.8K ﹤0.01% 3513
2026
Q1
$202K Buy
27,628
+16,510
+148% +$113K ﹤0.01% 3127
2025
Q4
$23.8K Sell
11,118
-1,672
-13% -$3.79K ﹤0.01% 3575
2025
Q3
$32K Sell
12,790
-3,143
-20% -$8.09K ﹤0.01% 3470
2025
Q2
$43.3K Buy
+15,933
New +$42.8K ﹤0.01% 3243

Other funds holding IBRX

Wealth Enhancement Advisory Services's IBRX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its ImmunityBio (IBRX) stake by 0.36% in Q3 2026, selling an estimated $767 and leaving 26,238 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #3496.

Wealth Enhancement Advisory Services first reported a position in IBRX in Q2 2025 and has held it in 6 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 26,238 shares of ImmunityBio worth $260K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 96 ImmunityBio shares in Q3 2026, an estimated $767.
  • ImmunityBio made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3496 holding.
  • Wealth Enhancement Advisory Services first reported a position in ImmunityBio in Q2 2025 and has held it in 6 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.